SIGA - NASDAQ
SIGA Technologies, Inc.
$4.40
+1.9%SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
At a Glance
Live SnapshotSIGA Technologies, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
SIGA Technologies, Inc. Income Statement
SIGA • NASDAQ
| SIGA Technologies, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
94.6M | 138.7M | 139.9M | 110.8M | 133.7M | 125M | 26.7M | 477.1M | 12.3M | 15M | 8.2M | 3.1M | 5.5M | 9M | 12.7M | 19.2M | 13.8M | 8.1M | 6.7M | 7.3M | |
GROSS PROFIT | ||||||||||||||||||||
(29.7M) | (31.3M) | (17.8M) | (10.4M) | (16.6M) | (25.7M) | (15.1M) | (108.3M) | (16.7M) | (19.7M) | (13.1M) | (10.8M) | (13.9M) | (18.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
64.9M | 107.4M | 122.1M | 100.3M | 117.1M | 99.2M | 11.7M | 368.8M | -4.4M | -4.7M | -5M | -7.7M | -8.3M | -9.2M | 12.7M | 19.2M | 13.8M | 8.1M | 6.7M | 7.3M | |
OPERATING INCOME | ||||||||||||||||||||
(41.2M) | (37.4M) | (38.5M) | (57.6M) | (28M) | (14.7M) | (14M) | (13.7M) | (13.2M) | (14.6M) | (11.6M) | (13.5M) | (14.7M) | (13.3M) | (44.1M) | (31.9M) | (25.7M) | (16.8M) | (14.2M) | (14.1M) | |
(3.1M) | (25.1M) | (22M) | (35.1M) | (18M) | (14.7M) | (13.3M) | (12.9M) | (12.3M) | (13.7M) | (10.6M) | (12.5M) | (13.2M) | (11.4M) | (25.7M) | (9.3M) | (8.3M) | (5.2M) | (4.2M) | (4.9M) | |
(6.5M) | (12.3M) | (16.4M) | (22.5M) | (9.9M) | (0.0) | (0.0) | (13M) | (16.7M) | (19.7M) | (13.1M) | (10.8M) | (13.9M) | (18.2M) | (18.4M) | (22.7M) | (17.4M) | (11.6M) | (9.9M) | (9.1M) | |
23.7M | 70M | 83.6M | 42.7M | 89.1M | 84.5M | -2.3M | 355.1M | -18.8M | -31M | -31M | -209.7M | -23.5M | -22.5M | -31.4M | -12.7M | -11.9M | -8.7M | -7.5M | -6.8M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3M) | (15.8M) | (15.5M) | (14.8M) | (14.1M) | (266.7K) | (455.8K) | (1.2M) | (173K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
6.7M | 0.0 | 0.0 | 0.0 | 0.0 | -3M | -15.8M | -15.5M | -14.8M | -14.1M | -266.7K | -455.8K | -1.2M | -173K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(31.5M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (726.1K) | (78.9M) | (16.8K) | -1.7M | (42.2K) | (1.1K) | (1.5K) | (522.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
6.7M | 6.1M | 4.2M | 1.4M | 218.9K | -11M | -7.9M | 56.5M | -19.5M | -8.7M | -8M | -2.3M | -1.3M | 632K | 8.9M | -37.5M | -5.7M | 137.5K | 1.8M | -3.1M | |
30.4M | 76.1M | 87.8M | 44.1M | 89.3M | 73.5M | -10.2M | 411.6M | -38.3M | -39.7M | -39M | -211.9M | -24.8M | -22.4M | -22.4M | -19.4M | -17.6B | -8.6M | -5.6M | -9.9M | |
NET INCOME | ||||||||||||||||||||
(7.1M) | (16.9M) | (19.7M) | (10.2M) | (19.9M) | (17.2M) | -2.9M | -10.2M | -2.1M | (13.9K) | (462K) | (53.5M) | -7.6M | -7.8M | -36M | (15.5M) | (5.7M) | (0.0) | (0.0) | (0.0) | |
23.3M | 59.2M | 68.1M | 33.9M | 69.5M | 56.3M | -7.2M | 421.8M | -36.2M | -39.7M | -39.5M | -265.5M | -17.2M | -14.5M | 13.6M | -28.2M | -17.6M | -8.6M | -5.6M | -9.9M |
SEC Filings
SIGA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 05, 2025 | August 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 05, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your SIGA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.